86.80
price down icon1.80%   -1.59
after-market After Hours: 86.80
loading
Arcellx Inc stock is traded at $86.80, with a volume of 1.30M. It is down -1.80% in the last 24 hours and up +19.38% over the past month. Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$88.39
Open:
$89.22
24h Volume:
1.30M
Relative Volume:
2.53
Market Cap:
$4.81B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-29.03
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+2.03%
1M Performance:
+19.38%
6M Performance:
+53.19%
1Y Performance:
+4.70%
1-Day Range:
Value
$86.12
$90.41
1-Week Range:
Value
$83.33
$90.41
52-Week Range:
Value
$47.86
$107.37

Arcellx Inc Stock (ACLX) Company Profile

Name
Name
Arcellx Inc
Name
Phone
240-327-0603
Name
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Name
Employee
163
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ACLX's Discussions on Twitter

Compare ACLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACLX
Arcellx Inc
86.80 4.90B 76.81M -162.42M -122.49M -2.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-25 Initiated Citigroup Buy
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-03-24 Initiated Cantor Fitzgerald Overweight
May-31-24 Initiated Piper Sandler Overweight
Mar-07-24 Initiated Morgan Stanley Overweight
Jan-04-24 Reiterated Needham Buy
Dec-19-23 Initiated Scotiabank Sector Outperform
Oct-30-23 Initiated TD Cowen Outperform
Oct-17-23 Initiated UBS Buy
May-18-23 Initiated Truist Buy
Apr-14-23 Initiated Robert W. Baird Outperform
Mar-14-23 Initiated Stifel Buy
Feb-13-23 Initiated H.C. Wainwright Buy
Dec-13-22 Resumed BofA Securities Buy
Oct-31-22 Initiated Guggenheim Buy
Oct-27-22 Initiated Needham Buy
Jul-20-22 Initiated Canaccord Genuity Buy
Mar-01-22 Initiated BofA Securities Buy
Mar-01-22 Initiated SVB Leerink Outperform
View All

Arcellx Inc Stock (ACLX) Latest News

pulisher
Oct 12, 2025

Analyzing recovery setups for Arcellx Inc. investors2025 Market Outlook & Weekly Top Gainers Alerts - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Arcellx (NASDAQ:ACLX) Rating Lowered to Hold at Cantor Fitzgerald - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Automated trading signals detected on Arcellx Inc.July 2025 Update & Verified Momentum Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Using data filters to optimize entry into Arcellx Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Arcellx Inc. showing signs of accumulationWeekly Market Summary & Fast Entry High Yield Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Arcellx assumed with a Neutral at Cantor Fitzgerald - TipRanks

Oct 10, 2025
pulisher
Oct 10, 2025

Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance

Oct 10, 2025
pulisher
Oct 09, 2025

Arcellx's (ACLX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

ACLX: Cantor Fitzgerald Assumes Coverage with Neutral Rating | A - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

What analyst consensus says on Arcellx Inc. stockWeekly Gains Report & Reliable Intraday Trade Plans - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Arcellx Inc Stock Analysis and ForecastIndustrial Stocks Review & Free Exceptional Market Positioning - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Oct 08, 2025
pulisher
Oct 07, 2025

Insider Selling: Michelle Gilson Sells 5,946 Shares of Arcellx Inc (ACLX) - GuruFocus

Oct 07, 2025
pulisher
Oct 06, 2025

Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position - TipRanks

Oct 06, 2025
pulisher
Oct 06, 2025

Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media

Oct 06, 2025
pulisher
Oct 05, 2025

Could Analyst Optimism on Neurotoxicity Give Arcellx (ACLX) an Edge in CAR-T Competition? - Sahm

Oct 05, 2025
pulisher
Oct 05, 2025

Will Arcellx Inc. see short term momentumEarnings Recap Summary & Growth Focused Stock Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 04:40:22 - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

A Fresh Look at Arcellx (ACLX) Valuation Following Scotiabank’s Regulatory Optimism and CAR-T Therapy Developments - Sahm

Oct 03, 2025
pulisher
Oct 03, 2025

Will Arcellx Inc. bounce back from current supportMarket Movers & Fast Entry High Yield Tips - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What moving averages say about Arcellx Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

BofA Securities Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $112 - 富途牛牛

Oct 03, 2025
pulisher
Sep 30, 2025

Christopher Heery Sells 21,034 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Arcellx CMO Heery sells $5851 in ACLX stock By Investing.com - Investing.com Nigeria

Sep 30, 2025
pulisher
Sep 30, 2025

Arcellx CMO Heery sells $5851 in ACLX stock - Investing.com India

Sep 30, 2025
pulisher
Sep 29, 2025

What drives Arcellx Inc stock priceEx-Dividend Date Alerts & Budget Friendly Growth - earlytimes.in

Sep 29, 2025
pulisher
Sep 28, 2025

Using portfolio simulators with Arcellx Inc. includedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com

Sep 28, 2025
pulisher
Sep 27, 2025

Arcellx CMO Heery sells $993k in ACLX stock - Investing.com India

Sep 27, 2025
pulisher
Sep 26, 2025

Arcellx CMO Heery sells $993k in ACLX stock By Investing.com - Investing.com Nigeria

Sep 26, 2025
pulisher
Sep 26, 2025

Arcellx (NASDAQ:ACLX) Insider Sells $993,167.52 in Stock - MarketBeat

Sep 26, 2025
pulisher
Sep 24, 2025

CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛

Sep 24, 2025
pulisher
Sep 24, 2025

Atle Fund Management AB Sells 18,439 Shares of Arcellx, Inc. $ACLX - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval - TipRanks

Sep 23, 2025
pulisher
Sep 23, 2025

Strs Ohio Acquires New Stake in Arcellx, Inc. $ACLX - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Christopher Heery Sells 300 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Arcellx (NASDAQ:ACLX) Insider Christopher Heery Sells 3,343 Shares - MarketBeat

Sep 23, 2025

Arcellx Inc Stock (ACLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Arcellx Inc Stock (ACLX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Gilson Michelle
CHIEF FINANCIAL OFFICER
Oct 06 '25
Sale
86.22
1,064
91,733
13,830
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Cap:     |  Volume (24h):